Energenesis Biomedical CO.,LTD. (TPE:6657)
Taiwan
· Delayed Price · Currency is TWD 44.95
-2.15 (-4.56%)
Mar 9, 2026, 2:38 PM CST
TPE:6657 Revenue
Energenesis Biomedical CO.,LTD. had revenue of 1.58M TWD in the quarter ending September 30, 2025, a decrease of -25.20%. This brings the company's revenue in the last twelve months to 7.46M, up 0.91% year-over-year. In the year 2024, Energenesis Biomedical CO.,LTD. had annual revenue of 7.75M with 8.26% growth.
Revenue (ttm)
7.46M
Revenue Growth
+0.91%
P/S Ratio
534.56
Revenue / Employee
n/a
Employees
35
Market Cap
3.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.75M | 591.00K | 8.26% |
| Dec 31, 2023 | 7.16M | -193.00K | -2.63% |
| Dec 31, 2022 | 7.35M | -138.00K | -1.84% |
| Dec 31, 2021 | 7.49M | 408.00K | 5.76% |
| Dec 31, 2020 | 7.08M | 830.00K | 13.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.59B |
| Formosa Pharmaceuticals | 12.16M |
| Genovate Biotechnology | 492.41M |
| BioGend Therapeutics | 222.34M |
| Senhwa Biosciences | 1.08M |
| ACRO Biomedical | 36.50M |
| Sagittarius Life Science | 424.44M |
| BRIM Biotechnology | 3.17M |